Yikes! Motley Fool Echoes My Views on Schering’s Foradil, at FDA Review Panel, Tomorrow. . . .

I am not entirely certain that I should be linking his, here, as “the Fool” is more-than-occasionally, um. . . just that, as to matters financial, but he does come out where I did, last week (12.05.08), about tomorrow’s 8:00 AM EST FDA Review Panel, at the Hilton, in Rockville, Maryland.

Before we read his pull-quote, let me offer an FDA link to all reported Foradil “adverse events“, sorted by events involving patients less than 17 years of age — “The truth will set you free!” — now, do go read his whole note, but here is his Schering punch-line:

. . . .There’s also the possibility of removing Serevent and Foradil from the market altogether. Those two drugs only contain LABAs, while Advair and Symbicort have a steroid added to the mix. Glaxo argues that pulling the LABA-only drugs is unnecessary because they’re already co-prescribed with a steroid. . . .

We’ll know in about 28 hours.